Cite

HARVARD Citation

    Sakata, Y. et al. (2020). The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events. Asia-Pacific journal of clinical oncology. 16 (2), pp. e113-e117. [Online]. 
  
Back to record